Amarin Co. plc (NASDAQ:AMRN) Insider Sells $191,412.52 in Stock

Amarin Co. plc (NASDAQ:AMRN) insider Steven B. Ketchum sold 9,542 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $20.06, for a total transaction of $191,412.52. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

AMRN stock traded up $0.10 during midday trading on Wednesday, reaching $18.49. 8,526,149 shares of the company’s stock traded hands, compared to its average volume of 8,111,672. The company has a current ratio of 2.40, a quick ratio of 2.04 and a debt-to-equity ratio of 0.35. Amarin Co. plc has a 52-week low of $2.35 and a 52-week high of $23.33. The stock has a market cap of $5.89 billion, a P/E ratio of -47.41 and a beta of 1.27.

Amarin (NASDAQ:AMRN) last announced its earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.03). The firm had revenue of $77.30 million for the quarter, compared to analyst estimates of $73.87 million. During the same quarter in the prior year, the company posted ($0.08) earnings per share. The company’s revenue for the quarter was up 43.4% on a year-over-year basis. As a group, equities analysts forecast that Amarin Co. plc will post -0.19 earnings per share for the current year.

A number of analysts recently weighed in on AMRN shares. Cantor Fitzgerald set a $35.00 price objective on Amarin and gave the company a “buy” rating in a report on Friday, December 28th. SunTrust Banks restated a “buy” rating on shares of Amarin in a report on Monday, January 7th. Citigroup decreased their price objective on shares of Amarin to $20.00 in a research note on Tuesday, January 8th. Zacks Investment Research downgraded shares of Amarin from a “hold” rating to a “sell” rating in a report on Tuesday, January 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $51.00 price target on shares of Amarin in a report on Thursday, January 17th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $32.17.

Hedge funds and other institutional investors have recently modified their holdings of the stock. LPL Financial LLC boosted its position in shares of Amarin by 1.0% during the 4th quarter. LPL Financial LLC now owns 138,845 shares of the biopharmaceutical company’s stock valued at $1,890,000 after acquiring an additional 1,429 shares during the last quarter. Signature Estate & Investment Advisors LLC increased its stake in Amarin by 17.8% in the fourth quarter. Signature Estate & Investment Advisors LLC now owns 9,920 shares of the biopharmaceutical company’s stock valued at $135,000 after purchasing an additional 1,500 shares during the last quarter. Winslow Evans & Crocker Inc. increased its stake in Amarin by 150.0% in the first quarter. Winslow Evans & Crocker Inc. now owns 2,500 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 1,500 shares during the last quarter. MML Investors Services LLC increased its stake in Amarin by 7.5% in the fourth quarter. MML Investors Services LLC now owns 25,077 shares of the biopharmaceutical company’s stock valued at $341,000 after purchasing an additional 1,741 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its holdings in shares of Amarin by 266.3% in the fourth quarter. Global Retirement Partners LLC now owns 2,612 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 1,899 shares during the period. 48.32% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Amarin Co. plc (NASDAQ:AMRN) Insider Sells $191,412.52 in Stock” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.baseballdailydigest.com/news/2019/04/24/amarin-co-plc-amrn-insider-steven-b-ketchum-sells-9542-shares.html.

Amarin Company Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Featured Story: FAANG Stocks

Insider Buying and Selling by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.